FindTrial
Sign In

Risk factors of poor prognosis in patients with pyrrolidine alkaloids induced hepatic sinusoidal obstruction syndrome after anticoagulation-TIPS treatment

Risk factors of poor prognosis in patients with pyrrolidine alkaloids induced hepatic sinusoidal obstruction syndrome after anticoagulation-TIPS treatment

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000040899
Enrollment
Unknown
Registered
2020-12-14
Start date
2020-12-20
Completion date
Unknown
Last updated
2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatic sinusoidal obstruction syndrome

Interventions

Survival group vs death group:Nil

Sponsors

Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Aged between 18 and 80 years; (2) clear diagnosis of PA-HSOS (in line with Nanjing criteria); (3) received TIPS therapy (with or without anticoagulation history).

Exclusion criteria

Exclusion criteria: (1) Patients who refused to be followed-up or follow-up time after TIPS therapy < 6.0 months; (2) The loss of most of the clinical data; (3) Patients with malignant tumor or other severe diseases; (4) TIPS failure (unsuccessful TIPS procedure or shunt dysfunction in one month after TIPS).

Design outcomes

Primary

MeasureTime frame
blood tests;ultrasound;—

Countries

China

Contacts

Public ContactZhuge Yuzheng

Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School

Yuzheng9111963@aliyun.com+86 15996289206

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026